These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
420 related articles for article (PubMed ID: 33156925)
1. Outcomes of patients with large B-cell lymphoma progressing after axicabtagene ciloleucel therapy. Spiegel JY; Dahiya S; Jain MD; Tamaresis J; Nastoupil LJ; Jacobs MT; Ghobadi A; Lin Y; Lunning M; Lekakis L; Reagan P; Oluwole O; McGuirk J; Deol A; Goy A; Vu K; Andreadis C; Munoz J; Bennani NN; Vose JM; Dorritie KA; Neelapu SS; Locke FL; Rapoport AP; Hill BT; Miklos DB Blood; 2021 Apr; 137(13):1832-1835. PubMed ID: 33156925 [No Abstract] [Full Text] [Related]
2. Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma. Neelapu SS; Jacobson CA; Oluwole OO; Munoz J; Deol A; Miklos DB; Bartlett NL; Braunschweig I; Jiang Y; Kim JJ; Zheng L; Rossi JM; Locke FL Blood; 2020 Jun; 135(23):2106-2109. PubMed ID: 32181801 [No Abstract] [Full Text] [Related]
3. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Locke FL; Ghobadi A; Jacobson CA; Miklos DB; Lekakis LJ; Oluwole OO; Lin Y; Braunschweig I; Hill BT; Timmerman JM; Deol A; Reagan PM; Stiff P; Flinn IW; Farooq U; Goy A; McSweeney PA; Munoz J; Siddiqi T; Chavez JC; Herrera AF; Bartlett NL; Wiezorek JS; Navale L; Xue A; Jiang Y; Bot A; Rossi JM; Kim JJ; Go WY; Neelapu SS Lancet Oncol; 2019 Jan; 20(1):31-42. PubMed ID: 30518502 [TBL] [Abstract][Full Text] [Related]
4. Development and Use of the Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy Axicabtagene Ciloleucel in Large B-Cell Lymphoma: A Review. Locke FL; Go WY; Neelapu SS JAMA Oncol; 2020 Feb; 6(2):281-290. PubMed ID: 31697310 [TBL] [Abstract][Full Text] [Related]
5. Axicabtagene ciloleucel and brexucabtagene autoleucel in relapsed and refractory diffuse large B-cell and mantle cell lymphomas. Reagan PM; Friedberg JW Future Oncol; 2021 Apr; 17(11):1269-1283. PubMed ID: 33448873 [TBL] [Abstract][Full Text] [Related]
6. Resource utilization in patients with large B-cell lymphoma receiving tisagenlecleucel and axicabtagene ciloleucel. Mian A; Wei W; Hamilton BK; Winter AM; Khouri J; Pohlman B; Gerds AT; Jagadeesh D; Anwer F; Kalaycio M; Dean RM; Sobecks R; Caimi PF; Hill BT; Majhail NS Bone Marrow Transplant; 2023 May; 58(5):590-593. PubMed ID: 36774431 [No Abstract] [Full Text] [Related]
7. Axicabtagene ciloleucel for relapsed or refractory lymphoma after prior treatment with a different CD19-directed CAR T-cell therapy. Chow VA; Gopal AK; Gauthier J; Tseng YD; Turtle CJ; Maloney DG; Shadman M Blood Adv; 2020 Oct; 4(19):4869-4872. PubMed ID: 33031539 [TBL] [Abstract][Full Text] [Related]
8. Delayed neurotoxicity after axicabtagene ciloleucel therapy in relapsed refractory diffuse large B-cell lymphoma. Badar T; Johnson BD; Hamadani M Bone Marrow Transplant; 2021 Mar; 56(3):683-685. PubMed ID: 32782349 [No Abstract] [Full Text] [Related]
9. Axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma patients in complete metabolic response. Jallouk AP; Gouni S; Westin J; Feng L; Mistry H; Steiner RE; James J; Noorani M; Horowitz S; Puebla-Osorio N; Fayad LE; Iyer SP; Hawkins M; Flowers CR; Ahmed S; Nastoupil LJ; Kebriaei P; Shpall EJ; Neelapu SS; Nieto Y; Strati P Haematologica; 2023 Apr; 108(4):1163-1167. PubMed ID: 36384251 [No Abstract] [Full Text] [Related]
10. [New European approvals: Tisagenlecleucel and Axicabtagene ciloleucel CAR-T cells - Follicular lymphoma after at least two and three prior lines of therapy]. Cordeil S; Bachy E Bull Cancer; 2022 Nov; 109(11):1106-1108. PubMed ID: 36088178 [No Abstract] [Full Text] [Related]
11. Axicabtagene ciloleucel, a first-in-class CAR T cell therapy for aggressive NHL. Roberts ZJ; Better M; Bot A; Roberts MR; Ribas A Leuk Lymphoma; 2018 Aug; 59(8):1785-1796. PubMed ID: 29058502 [TBL] [Abstract][Full Text] [Related]
12. Axicabtagene Ciloleucel Chimeric Antigen Receptor T Cell Therapy in Lymphoma With Secondary Central Nervous System Involvement. Novo M; Ruff MW; Skrabek PJ; Lin Y Mayo Clin Proc; 2019 Nov; 94(11):2361-2364. PubMed ID: 31685159 [No Abstract] [Full Text] [Related]
13. Safety of axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma in an elderly intercity population. Shapiro LC; Mustafa J; Lombardo A; Khatun F; Joseph F; Gillick K; Naik A; Elkind R; Abreu M; Fehn K; de Castro A; Pradhan K; Binakaj D; Nelson R; Paroder M; Uehlinger J; Gritsman K; Alejandro Sica R; Kornblum N; Shastri A; Mantzaris I; Bachier-Rodriguez L; Verma A; Braunschweig I; Goldfinger M Bone Marrow Transplant; 2021 Jul; 56(7):1761-1763. PubMed ID: 33846558 [No Abstract] [Full Text] [Related]
14. Clinical activity of axicabtagene ciloleucel in adult patients with Richter syndrome. Kittai AS; Bond DA; William B; Saad A; Penza S; Efebera Y; Larkin K; Wall SA; Choe HK; Bhatnagar B; Vasu S; Brammer J; Shindiapina P; Long M; Mims A; O'Donnell L; Bhat SA; Rogers KA; Woyach JA; Byrd JC; Jaglowski SM Blood Adv; 2020 Oct; 4(19):4648-4652. PubMed ID: 33002129 [No Abstract] [Full Text] [Related]
15. Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed/refractory diffuse large B-cell lymphoma. Chow VA; Shadman M; Gopal AK Blood; 2018 Aug; 132(8):777-781. PubMed ID: 29914976 [TBL] [Abstract][Full Text] [Related]
16. Axicabtagene ciloleucel CD19 CAR-T cell therapy results in high rates of systemic and neurologic remissions in ten patients with refractory large B cell lymphoma including two with HIV and viral hepatitis. Abbasi A; Peeke S; Shah N; Mustafa J; Khatun F; Lombardo A; Abreu M; Elkind R; Fehn K; de Castro A; Wang Y; Derman O; Nelson R; Uehlinger J; Gritsman K; Sica RA; Kornblum N; Mantzaris I; Shastri A; Janakiram M; Goldfinger M; Verma A; Braunschweig I; Bachier-Rodriguez L J Hematol Oncol; 2020 Jan; 13(1):1. PubMed ID: 31900191 [TBL] [Abstract][Full Text] [Related]
17. Understanding and Managing Large B Cell Lymphoma Relapses after Chimeric Antigen Receptor T Cell Therapy. Byrne M; Oluwole OO; Savani B; Majhail NS; Hill BT; Locke FL Biol Blood Marrow Transplant; 2019 Nov; 25(11):e344-e351. PubMed ID: 31279751 [TBL] [Abstract][Full Text] [Related]
18. Axicabtagene Ciloleucel: Clinical Data for the Use of CAR T-cell Therapy in Relapsed and Refractory Large B-cell Lymphoma. Halford Z; Anderson MK; Bennett LL Ann Pharmacother; 2021 Mar; 55(3):390-405. PubMed ID: 32698673 [TBL] [Abstract][Full Text] [Related]
19. New Treatment for Relapsed or Refractory Large B-cell lymphoma. Aschenbrenner DS Am J Nurs; 2021 Jun; 121(6):21-22. PubMed ID: 34009160 [TBL] [Abstract][Full Text] [Related]
20. New Second-Line Treatment for B-Cell Lymphoma. Aschenbrenner DS Am J Nurs; 2022 Aug; 122(8):23. PubMed ID: 35862599 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]